Patents Assigned to Quantum Genomics
  • Compounds and compositions comprising the same for treating hypertension or heart failure
    Patent number: 11345658
    Abstract: The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 31, 2022
    Assignees: QUANTUM GENOMICS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COLLEGE DE FRANCE
    Inventors: Fabrice Balavoine, Delphine Compere, Mathilde Keck, Yannick Marc, Catherine Llorens-Cortes, Solène E. Boitard
  • Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same
    Patent number: 11192907
    Abstract: The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: December 7, 2021
    Assignees: QUANTUM GENOMICS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COLLEGE DE FRANCE
    Inventors: Fabrice Balavoine, Delphine Compere, Catherine Llorens-Cortes, Yannick Marc
  • Combination of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
    Patent number: 10959938
    Abstract: The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S?)4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 30, 2021
    Assignee: Quantum Genomics
    Inventors: Catherine Llorens-Cortes, Yannick Marc, Ji Gao-Desliens, Fabrice Balavoine, Lionel Segard
  • Crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine
    Patent number: 9487477
    Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 8, 2016
    Assignee: Quantum Genomics
    Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat
  • Method for the preparation of (3S,3S?) 4,4?-disulfanediylbis (3-aminobutane 1-sulfonic acid)
    Patent number: 9340497
    Abstract: The present invention relates to a new method for the preparation of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) in five steps from (S)-ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate A.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: May 17, 2016
    Assignee: QUANTUM GENOMICS
    Inventors: Fabrice Balavoine, Jonathan Madec, Jean-Marie Schneider, Gerard Coquerel, Nicolas Couvrat, Yohann Cartigny, Marie-Noelle Petit
  • Crystalline phase of (3S.3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) with L-lysine
    Patent number: 9278921
    Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 8, 2016
    Assignee: Quantum Genomics
    Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat
  • Method for the preparation of (3S, 3S?) 4,4?-disulfanediylbis (3-aminobutane 1-sulfonic acid)
    Patent number: 9187418
    Abstract: The present invention relates to a new method for the preparation of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) in five steps from (S)-ethyl 2-(benzyloxycarbonylamino)-4-(neopentyloxysulfonyl)butanoate A.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: November 17, 2015
    Assignee: QUANTUM GENOMICS
    Inventors: Fabrice Balavoine, Jonathan Madec, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat, Yohann Cartigny, Marie-Noëlle Petit
  • CRYSTALLINE PHASE OF (3S.3S') 4,4'-DISULFANEDIYLBIS(3-AMINOBUTANE 1-SULFONIC ACID) WITH L-LYSINE
    Publication number: 20150284325
    Abstract: The present invention relates to a new crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one crystalline phase of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and to the therapeutic or prophylactic use of such crystalline phase and compositions comprising the same.
    Type: Application
    Filed: October 22, 2013
    Publication date: October 8, 2015
    Applicant: Quantum Genomics
    Inventors: Fabrice Balavoine, Jean-Marie Schneider, Gérard Coquerel, Nicolas Couvrat